BAKER BROS ADVISORS LLC 13D and 13G filings for Kymera Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-08-22 4:15 pm Purchase |
2024-08-21 | 13D | Kymera Therapeutics, Inc. KYMR |
BAKER BROS ADVISORS LLC | 6,001,262 9.300% |
3,556 (+0.06%) |
Filing |
| 2024-04-01 08:57 am Purchase |
2024-03-28 | 13D | Kymera Therapeutics, Inc. KYMR |
BAKER BROS ADVISORS LLC | 5,997,706 9.800% |
1,778 (+0.03%) |
Filing |
| 2024-01-10 4:52 pm Purchase |
2023-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
BAKER BROS ADVISORS LLC | 5,995,928 10.800% |
3,116,103 (+108.20%) |
Filing |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
BAKER BROS ADVISORS LLC | 2,879,825 5.200% |
2,879,825 (New Position) |
Filing |